Cancers, Vol. 11, Pages 1203: Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care

Cancers, Vol. 11, Pages 1203: Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care Cancers doi: 10.3390/cancers11081203 Authors: Baptiste Louveau Fanelie Jouenne Coralie Reger de Moura Aurelie Sadoux Barouyr Baroudjian Julie Delyon Florian Herms Adele De Masson Laetitia Da Meda Maxime Battistella Nicolas Dumaz Celeste Lebbe Samia Mourah In BRAFV600mut metastatic melanoma, the combination of BRAF and MEK inhibitors (BRAFi, MEKi) has undergone multiple resistance mechanisms, limiting its clinical benefit and resulting in the need for response predicting biomarkers. Based on phase III clinical trial data, several studies have previously explored baseline genomic features associated with response to BRAFi + MEKi. Using a targeted approach that combines the examination of mRNA expression and DNA alterations in a subset of genes, we performed an analysis of baseline genomic alterations involved in MAPK inhibitors’ resistance in a real-life cohort of BRAFV600mut metastatic melanoma patients. Twenty-seven patients were included in this retrospective study, and tumor samples were analyzed when the BRAFi + MEKi therapy was initiated. The clinical characteristics of our cohort were consistent with previously published studies. The BRAFi + MEKi treatment was initiated in seven patients as a following-line treatment, and had a specific transcriptomic profile exhi...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research